INTRODUCTION

Follicular lymphoma (FL) is the second most common non-Hodgkin lymphoma (NHL)
overall and most common indolent NHL, with about 14,000 diagnosed cases estimated annually in the United States. 1 Accounting for up to 20% of NHL cases globally, FL is a slow-growing tumor that often responds well to initial therapy. 2 However, advanced-stage FL is an incurable disease characterized by frequent relapses, often with increasing aggressiveness, and the ability to transform into more aggressive lymphoid malignancies. 3 The variable disease course and lack of cure has resulted in variable treatment strategies, without a standard of care. Overall survival (OS) in FL has improved with the incorporation of the immunotherapy rituximab over the past decade. 4, 5 However, heterogeneity in FL outcomes persists. Relapse occurs in up to 20% of patients within the first 24 months of first-line treatment, and confers a poor prognosis. [6] [7] [8] To date, a limited number of prognostic parameters have been identified for predicting outcomes in
FL.
The selection of cancer diagnostics and treatments may depend on a patient's insurance status. [9] [10] [11] Patients with no insurance or Medicaid, when compared to those with private insurance, are more likely to be diagnosed at advanced stage for all cancers. 9 Disparities in treatment and outcomes related to insurance status have been examined for some patients with aggressive NHL, 12 but are less clear for FL and other indolent NHLs. For instance, NHL patients with Medicaid or no insurance are less likely to receive immunotherapy treatments like rituximab, a therapy known to improve FL outcomes. 13, 14 In another study, older adolescents and young adults with lymphoma had a wider gap between cancer symptom onset and diagnosis if they had Medicaid or no insurance rather than if they had private insurance. 15 In other studies,
For personal use only. on July 26, 2018. by guest www.bloodjournal.org From 2 patients without private insurance have been shown to have significantly worse outcomes for two aggressive lymphomas: diffuse large B-cell lymphoma and Hodgkin lymphoma. 12, 16 For patients with FL, lower neighborhood socioeconomic status is associated with substantially poorer survival, suggesting access to care plays an important role in outcomes. 17 The social determinants of FL prognosis remain unclear and literature on the relationship between access to care and FL outcomes is scarce. We examined the relationship between insurance status and OS for FL in a national patient cohort.
For personal use only. on July 26, 2018. by guest www.bloodjournal.org From and were HIV-negative. Only HIV-negative patients were included in this study due to significant confounding by HIV status on the relationship between insurance status and survival.
METHODS
Data Source
Patients were excluded if insurance status was missing (n=759) , or the reporting facility was not CoC-accredited in the follow-up years (n=4598), as were those who had government-sponsored insurance (Veterans Affairs and Indian/Public Health Services) (n=497), since this category combines various heterogenous populations in a small sample size (shown in Figure 1 ).
Study Variables
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Patients with Medicare age < 65 years were more likely to have B-symptoms and comorbidities (Supplementary Table 1 ). Meanwhile, patients with Medicare age ≥ 65 years were significantly more likely to have comorbidities and receive treatment with systemic therapy than those privately insured (Supplemental Table 2 ).
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The OS rates for privately insured, uninsured, Medicaid-insured, and Medicare-insured patients age < 65 were 90%, 78%, 80% and 78%, respectively, at 5 years (Kaplan-Meier curves shown in Figure 2 ). OS was significantly worse for uninsured, Medicaid-insured, and Medicare-insured patients age < 65 years compared to those privately insured with HRs of 2. 34 The findings of the study indicate that improving access to affordable, quality healthcare may reduce disparities in survival for those currently lacking coverage.
In our additional analyses, private insurance remained a significant predictor of improved OS relative to no insurance, Medicaid, and Medicare when stratified by early and advanced stage for patients age < 65 years (Supplemental Figure 2 ) and for patients age Our results showed that patients with Medicaid, Medicare or no insurance age < 65 years were more likely to have a delay in treatment and were more likely to receive systemic therapy than their privately insured counterparts; however, these associations were not found in the elderly cohort. For both cohorts, a delay in treatment and treatment other than systemic therapy were associated with improved survival. This observed improved outcome is likely due to those patients having less severe disease at diagnosis. 40 The Affordable Care Act (ACA), passed in 2010 has improved patient access to care with more adults connecting to the health care system, obtaining a regular source of care, and being able to afford the care they required. 41, 42 Coverage expansion has been associated with earlier oncologic diagnosis and timelier oncologic care. 43, 44 The expansion of Medicaid has been successful in improving mortality, with the largest improvement in healthcare-amenable conditions like cancer. 45 Although insurance through Medicaid can be associated with improved outcomes compared with no insurance; the benefits of Medicaid may be falsely lowered due to uninsured patients waiting until they qualified for Medicaid to see a physician about their cancer symptoms. 46 This is suggested by the significantly increased likelihood of Medicaid patients presenting in an advanced stage. It is also worth noting that
Medicaid insurance still confers a worse OS for FL than private insurance, though this effect may be somewhat exaggerated. Healthcare policy should be based on evidence, and, for patients with FL, improving access to care for those who are unable to afford private insurance has the potential to substantially improve outcomes. 47 In conclusion, our study finds that insurance status contributes to survival disparities in FL. Future studies on outcomes in FL should include insurance status as an important predictor.
Further research on prognosis for FL should examine the impact of public policy, such as the passage of the ACA, on FL outcomes, as well as examine other factors that influence access to care, such as individual-level socioeconomic status, regular primary care visits, access to prescription medications, and care affordability. of the National Institute of Health under Award Number UL1TR000454. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
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